You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Dopamine Transporter Correlates and Occupancy by Modafinil in Cocaine-Dependent Patients: A Controlled Study With High-Resolution PET and [11C]-PE2I
|
|---|---|
| Published in |
Neuropsychopharmacology, February 2016
|
| DOI | 10.1038/npp.2016.28 |
| Pubmed ID | |
| Authors |
Laurent Karila, Claire Leroy, Manon Dubol, Christian Trichard, Audrey Mabondo, Catherine Marill, Albertine Dubois, Nadège Bordas, Jean-Luc Martinot, Michel Reynaud, Eric Artiges |
| Abstract |
Modafinil is a candidate compound for the treatment of cocaine addiction that binds to the dopamine transporter (DAT) in healthy humans, as observed by positron emission tomography (PET). This mechanism, analogous to that of cocaine, might mediate a putative therapeutic effect of modafinil on cocaine dependence. Though, the binding of modafinil to DAT has never been assessed in cocaine-dependent patients. We aimed at quantifying the DAT availability during a controlled treatment by modafinil, and its clinical and psychometric correlates in cocaine-dependent patients at the onset of abstinence initiation. Twenty-nine cocaine-dependent male patients were enrolled in a 3-month trial for cocaine abstinence. Modafinil was used in a randomized double-blind placebo-controlled design and was administered as follows: 400 mg/day for 26 days, then 300 mg/day for 30 days and 200 mg/day for 31 days. Participants were examined twice during a seventeen-day hospitalization for their DAT availability using PET and [(11)C]-PE2I, and for assessments of craving, depressive symptoms, working memory, and decision-making. Cocaine abstinence was further assessed during a ten-week outpatient follow-up period. Baseline [(11)C]-PE2I binding potential covaried with risk-taking and craving index in striatal and extrastriatal regions. A 65.6% decrease of binding potential was detected in patients receiving modafinil for two weeks, whereas placebo induced no significant change. During hospitalization, an equivalent improvement in clinical outcomes was observed in both treatment groups, and during the outpatient follow-up there were more therapeutic failures in the modafinil-treated group. Therefore, these results do not support the usefulness of modafinil to treat cocaine addiction.Neuropsychopharmacology accepted article preview online, 19 February 2016. doi:10.1038/npp.2016.28. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 6 | 40% |
| Germany | 1 | 7% |
| Spain | 1 | 7% |
| Unknown | 7 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 87% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Iran, Islamic Republic of | 1 | 1% |
| Unknown | 88 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 18% |
| Student > Bachelor | 14 | 15% |
| Researcher | 9 | 10% |
| Student > Doctoral Student | 8 | 9% |
| Student > Master | 8 | 9% |
| Other | 11 | 12% |
| Unknown | 25 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 21% |
| Psychology | 16 | 18% |
| Neuroscience | 5 | 5% |
| Nursing and Health Professions | 5 | 5% |
| Agricultural and Biological Sciences | 4 | 4% |
| Other | 7 | 8% |
| Unknown | 35 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 August 2016.
All research outputs
#3,783,467
of 22,849,304 outputs
Outputs from Neuropsychopharmacology
#1,772
of 4,111 outputs
Outputs of similar age
#68,437
of 400,372 outputs
Outputs of similar age from Neuropsychopharmacology
#31
of 46 outputs
Altmetric has tracked 22,849,304 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,111 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.1. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 400,372 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.